SGLT2 Inhibitors and GLP-1 Receptor Agonists
Large cardiovascular outcome trials show that both drug classes independently reduce cardiovascular events in patients with established CVD or very high risk. In Danish baseline screening data, SGLT2i and GLP1ra use was similar regardless…
1 sources - 4 claims
Large cardiovascular outcome trials show that both drug classes independently reduce cardiovascular events in patients with established CVD or very high risk. In Danish baseline screening data, SGLT2i and GLP1ra use was similar regardless of CAC score. Their role in primary cardiovascular prevention and the additive effect of combining them remain unsettled. SGLT2 inhibitors and GLP-1 receptor agonists have changed the therapeutic landscape for cardiovascular risk management in diabetes.